Clinical Trial Results for Xinbao Pill in Microvascular Angina
Overview
Coronary microvascular dysfunction is a growing concern, but effective treatments are still lacking. This study examined the effectiveness of the Xinbao pill for patients suffering from microvascular angina (MVA).
Study Details
A total of 200 patients with MVA were enrolled in this study between January 2020 and June 2021. They were randomly divided into two groups:
- Control Group (100 patients): Received standard treatment.
- Observation Group (100 patients): Received standard treatment plus Xinbao pill.
Results
Both groups showed improvement in clinical outcomes and angina symptoms after treatment, but the observation group experienced significantly better results:
- Total clinical effective rate increased.
- Angina symptom scores improved more in the observation group.
- Levels of nitric oxide (NO) and coronary flow reserve (CFR) increased.
- Exercise time on a treadmill improved significantly.
Symptom Reduction
Patients in the observation group had:
- Fewer episodes of exertional angina.
- Lower levels of ET-1, an inflammatory factor.
- Reduced levels of serum inflammatory factors.
- Less severe ST segment depression on tests.
Conclusion
The Xinbao pill significantly reduces angina symptoms and inflammatory factors in MVA patients, enhancing overall treatment effectiveness and safety.
Next Steps in Clinical Practice
Define Measurable Outcomes
Set clear goals for the use of Xinbao pill in treating microvascular angina to improve clinical management.
Select AI Tools
Choose AI solutions that match specific clinical needs related to the Xinbao pill treatment.
Implement Step by Step
Begin with a pilot project to track the results of Xinbao pill treatments, utilizing AI solutions to analyze real-world impacts.
Contact Us for AI Solutions in Medical Management
For inquiries, reach out via:
